April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement - 04/30/2026
The FDA’s Oncologic Drugs Advisory Committee will meet on April 30, 2026 to evaluate two AstraZeneca submissions: NDA 220359 for camizestrant tablets combined with CDK4/6 inhibitors in ESR1‑mutated hormone‑receptor‑positive breast cancer, and sNDA 218197/S‑004 for Truqap (capivasertib) plus abiraterone in PTEN‑deficient metastatic hormone‑sensitive prostate cancer. The public can submit written or electronic comments through April 29, 2026, and oral presenters must apply by April 8, 2026. The meeting will be webcast live, with materials posted online in advance. Recommendations are non‑binding but heavily influence FDA approval decisions.
Watch SynBioBeta2026 Live Anywhere, No Travel Needed
Visas. Travel costs. Time away from the lab or the office. Not everyone can make it to San Jose for #SynBioBeta2026 That's exactly why we built the livestream. 160+ sessions. 200+ speakers. Three days of Main Stage content streaming directly to your...
Intellia’s Data Reveal Tees Up FDA Filing for CRISPR-Based In Vivo Gene-Editing Med
Intellia Therapeutics filed a rolling FDA submission for lonvo‑z, its CRISPR‑based in‑vivo gene‑editing therapy for hereditary angioedema (HAE). In a placebo‑controlled Phase 3 trial of 80 patients, a single infusion cut swelling attacks by 87% versus placebo and left 62% of...
ERAS-0015 Linked to Fatal Pneumonitis After Care Withdrawal
$ERAS safety update, from tonight's slides. One Grade 3 TRAE of pneumonitis progressed to Grade 5 after withdrawal of supportive care per patient decision. The patient was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma who received 24 mg of ERAS-0015. The patient had...
FDA Grants Breakthrough Designation for Efimosfermin for MASH
GSK’s investigational liver drug efimosfermin received FDA breakthrough therapy designation for metabolic dysfunction‑associated steatohepatitis (MASH). A phase‑2 trial showed 45.2% of patients achieved at least one‑stage fibrosis improvement versus 20.6% on placebo, and 67.7% attained MASH resolution compared with 29.4%...
Gluten Triggers Immune Response at 3 Mg, Below Current Labeling Limits
Researchers in Australia demonstrated that a single gluten dose as low as 3 mg provokes measurable immune activation in celiac disease patients, well under the 20 ppm threshold used for gluten‑free labeling. The finding raises questions about the adequacy of current safety...
NUS Researchers Cut Fertilizer Use 15% with Microneedle Plant Patches
Scientists at the National University of Singapore have created dissolvable microneedle patches that deliver beneficial microbes directly into plant leaves and stems. The technique reduced biofertilizer application by 15% and accelerated growth in greenhouse kale and choy sum, offering a...
FDA Grants Accelerated Approval to Regeneron's Otarmeni Gene Therapy for Genetic Hearing Loss
The U.S. FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec‑cwha), the first in‑vivo gene therapy for OTOF‑related sensorineural hearing loss. The decision, based on a 20‑patient CHORD trial, makes the treatment free for U.S. patients and expands...
NIH Studies Often Ignore Sex Differences, Hindering Precision Medicine
Less than half of NIH-funded health studies analyze results by sex, potentially overlooking critical differences that impact diagnosis, treatment, and drug development for both men and women. precisionmedicine
TytoCare Gets FDA De Novo Clearance for First AI Eardrum Diagnostic Tool
TytoCare announced FDA De Novo classification for its Tyto Insights™ for ENT Suite, the first AI-driven eardrum analysis device. The clearance creates a new regulatory category for AI ENT image analyzers and positions the company to address 20 million annual pediatric...
Pharma R&D Embraces Data Lakehouses, Boosting Speed and Cutting Costs
AstraZeneca, Illumina and Pfizer are moving their research data onto lakehouse platforms such as Databricks, Snowflake and Apache Iceberg. Pfizer reports a four‑fold query speed increase and a 57% reduction in total cost of ownership, signaling a sector‑wide shift toward...
Sona Nanotech Reports 60% Complete Response Rate in First‑Human Melanoma Trial
Sona Nanotech Inc. presented first‑in‑human data showing six complete responses out of ten late‑stage melanoma patients at the AACR meeting in San Diego and secured a slot at the upcoming ASCO conference. The results, derived from the company’s gold‑nanorod Targeted...
STAT+: Erasca Touts Strong, Though Preliminary, Results in Trial of Pancreatic and Lung Cancer Therapy
Erasca announced that its oral RAS‑targeting drug ERAS‑0015 produced tumor shrinkage in 40% of patients with advanced pancreatic cancer and 62% of those with advanced non‑small‑cell lung cancer. The early‑stage data, gathered from trials in the United States and China,...
Former Senator Ben Sasse Credits Experimental Cancer Drug for Extending Life
Former Nebraska senator Ben Sasse, battling terminal pancreatic cancer, says an experimental drug has given him additional months of life. The interview highlights the promise and uncertainty of cutting‑edge oncology treatments and fuels discussion about patient access to novel therapies.
A Treatment for Pre-Eclampsia May Be on the Horizon
Researchers have unveiled a blood‑filtering therapy that shows promise in treating pre‑eclampsia, a life‑threatening pregnancy complication. Early‑stage trials reported significant reductions in maternal blood pressure and improved organ function without harming the fetus. The approach works by extracorporeally removing circulating...
Pencil Beam Laser Could Help Researchers Design Brain-Targeted Therapies
MIT researchers have demonstrated that laser light can self‑organize into a tightly focused "pencil beam," enabling a new bioimaging modality that is both faster and high‑resolution. In proof‑of‑concept experiments the team captured three‑dimensional images of the human blood‑brain barrier 25...
Serif Biomedicines Raises $50 Million
Flagship Pioneering announced the creation of Serif Biomedicines, a new biotech focused on Modified DNA therapeutics. The company emerges after five years of platform development. Flagship pledged an initial $50 million to fund the launch. The venture positions Serif to pursue...
FDA May Be Poised To Collaborate With Paradigm On AI Model
The FDA is reportedly preparing an announcement on real‑world evidence (RWE) that could involve a partnership with Paradigm on its new SPIRAL artificial‑intelligence model. SPIRAL is designed to generate RWE for post‑approval and late‑stage clinical studies, leveraging large‑scale health‑data sources....
Future Antidepressant Could Transform Millions Like Tirzepatide
Imagine a drug for reducing depression or anxiety that is as powerful as Tirzepatide is for reducing hunger. I think tens of millions of people will be on drugs like this in the next 5 years and I think it...
Over Half of Gray Market Peptides Fail Quality Standards
New pre-print on gray market peptides using @finnrick_tests data: 41.6% to 71.1% of gray market peptide samples failed to meet basic quality criteria, and measurable endotoxin contamination was present in 15% of samples. @Krysia830073
Autism Genetics Linked to Reduced Brain Cell Fiber Density
Researchers analyzed brain imaging and genetic data from over 30,000 UK Biobank adults and nearly 5,000 ABCD children, finding that higher polygenic scores for autism consistently correlate with lower neurite density across the cortex and major white‑matter tracts. The association...
Low Post‑Surgery Klotho Predicts Inflammation and Cognitive Decline
Lower levels of the anti-aging protein Klotho after surgery were strongly linked to higher inflammation and worse cognitive function in patients with postoperative cognitive dysfunction (POCD). This suggests Klotho could be a useful early biomarker—and possibly a treatment target—for predicting...
Erasca Shows Promising 40% PDAC, 62% NSCLC Responses
$ERAS Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy $RVMD 40% uORR in PDAC; 62% uORR in NSCLC https://t.co/90BkD7tBeN
Randomized Radical Reaction Leads to Selective Cyclizations
A new “radical sampling” strategy reported in JACS (2026) enables selective formation of six‑membered nitrogen heterocycles such as piperidines and morpholines from simple aldehyde and amine precursors. The method uses a light‑activated catalyst to generate radicals that compete between rapid...
Longevity Hype Outpaces Evidence; Cancer Risk Remains
This @NYTmag article on longevity science, reversing aging with cellular reprogramming, by @susandominus, is over the top. We have no proof that rejuvenation of a human organ is possible, no less the whole body, and there is risk of inducing...
NTLA Turns Red, Faces Cash‑Raise Dilemma
$NTLA finally red. Took longer than I expected. How do they raise the cash they need from here? Are they going to be forced to take on debt?
Withdrawn | Cancer Accelerated Approvals
The FDA has withdrawn 31 cancer drugs that were granted accelerated approval, spanning indications from lung and breast cancer to rare lymphomas. The most recent removal was Trodelvy for metastatic urothelial carcinoma on November 22, 2024. Withdrawals typically follow failed...
Exercise, Ibuprofen Reduce Cancer-Related Cognitive Impairment
A phase‑2 randomized trial of 86 chemotherapy patients found that a six‑week home‑based exercise program markedly improved cognitive performance, cutting Trail Making Test times by over 21 seconds compared with placebo. Low‑dose ibuprofen (200 mg twice daily) also yielded modest gains,...
A Brain Implant for Depression Is About to Be Tested in Humans
Motif Neurotech received FDA approval to begin a first‑in‑human study of its blueberry‑sized brain implant designed to treat severe depression. The device sits just above the dura and delivers wireless electrical stimulation to the central executive network, aiming to restore...
The Longevity Economy Is Built for the Rich
The episode examines the $6 trillion "longevity economy"—the booming market built around anti‑aging and wellness innovations—and highlights how its benefits are disproportionately accessible to the wealthy. It outlines macro trends driving investment in longevity, critiques the uneven distribution of cutting‑edge therapies,...
Kerry Facility Expansion Helps Meet Demand for Lactose-Free Dairy
Kerry announced a major expansion of its Carrigaline, Ireland biotechnology plant, boosting industrial‑scale production of lactase enzymes. The upgraded facility now supports processing of over 2 million tonnes of milk each year, helping dairy producers meet soaring demand for lactose‑free and...
How Does Integrated Fluid Management Enable Flexible Bioproduction Across Modalities?
At INTERPHEX 2026, Avantor senior vice president Jerry Keybl highlighted how integrated fluid management underpins scalable bioproduction across cell, gene and other therapeutic modalities. He argued that consistent, well‑characterized fluid paths from early development through commercial scale reduce variability and...
Veradermics Soars on Positive Data for Baldness Treatment
Veradermics announced that its experimental oral minoxidil pill, VDPHL01, achieved the primary endpoint in a Phase 3 trial, delivering a 30‑33 hair‑per‑cm² increase over six months versus placebo. The drug was well tolerated, with side‑effect rates matching placebo and no cardiac...
Eli Lilly Acquires Ajax to Strengthen JAK Pipeline
Lilly to buy startup Ajax in bid for a better JAK drug https://t.co/RMQQZ4mRFG $INCY $BMY $LLY $TAK #biotech #startups
Pam Marrone Targets Resistant Weeds with Cocktails of Microbial Metabolites as Bioherbicide Space Heats Up
Invasive Species Corporation (ISC), led by Pam Marrone, is developing bioherbicides that combine multiple microbial metabolites to tackle glyphosate‑resistant weeds. The company has advanced two lead candidates from greenhouse tests to extensive field trials across the Midwest and Southeast in...
Dispatch Biotherapeutics Launches First Clinical Trial
Remember Car June's new venture, Dispatch Biotherapeutics (raised $216 m since 2022)? Here's its first clinical trial: https://t.co/EIrZHSeHT8
Lilly to Acquire Ajax Therapeutics
Eli Lilly announced a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion in cash. Ajax’s lead candidate, AJ1-11095, is a first‑in‑class Type II JAK2 inhibitor currently in a Phase 1 study (AJX‑101) for myelofibrosis patients who have failed Type I JAK2...
Compass Shares Crash as ‘Confounding’ Survival Data Raise Approvability Questions for Bispecific
Compass Therapeutics reported that its bispecific antibody tovecimig failed to meet the secondary overall survival (OS) endpoint in the Phase 2/3 COMPANION‑002 trial, though it achieved a 56% reduction in progression risk, extending progression‑free survival (PFS) to 4.7 months versus 2.6...
University of Southampton and UCB to Develop Digital Antibodies with AI
The University of Southampton and biopharma firm UCB have launched the Digital Antibody Research Collaboration (DARC), a three‑year AI‑driven platform for in‑silico therapeutic antibody design. DARC aims to compress the typical ten‑to‑twelve‑year development timeline by automating molecule modeling, testing and...
This Dangerous Pregnancy Complication Is Common. A New Treatment Might Help
A novel blood‑filter that removes excess soluble Flt‑1 reduced the protein by roughly 17% in a pilot study of 16 women with early‑onset preeclampsia. The intervention modestly lowered blood pressure and proteinuria, allowing pregnancies to extend a median of 10...
Samsung Bioepis Releases Second Quarter 2026 US Biosimilar Market Report
Samsung Bioepis released its Q2 2026 U.S. Biosimilar Market Report, the thirteenth edition of the quarterly series. The report documents 92 FDA‑approved biosimilars across 20 molecules, with 67 (73 %) already launched, and notes a 60 % adoption rate for adalimumab biosimilars. It...
GDC-4198
Regor Therapeutics discovered GDC‑4198, an oral CDK4/2 inhibitor now owned by Genentech. The drug is in Phase 1/2 trials for advanced solid tumors, with a focus on breast cancer. It combines low‑nanomolar CDK4 potency with comparable CDK2 activity and roughly 20‑fold...
ESCMID Global 2026: Pritelivir Excels in Immunocompromised Refractory HSV Patients
Aicuris presented Phase III data for its oral helicase‑primase inhibitor pritelivir at ESCMID Global 2026. In the PRIOH‑1 trial of 101 immunocompromised adults with acyclovir‑refractory HSV, pritelivir achieved significantly higher lesion‑healing rates than investigator‑chosen IV or topical therapies. The drug also...
Mundipharma Announces Positive Topline Results From Phase III ReSPECT Trial Assessing ▼REZZAYO® (Rezafungin) for the Prophylaxis of Invasive Fungal Diseases...
Mundipharma reported that its Phase III ReSPECT trial met the primary endpoint, showing rezafungin (REZZAYO®) was non‑inferior to standard antifungal regimens for fungal‑free survival at Day 90 (60.7% vs 59.0%). The once‑weekly echinocandin demonstrated a comparable safety profile with fewer drug‑drug interactions...
Missouri Analytical Laboratories Inc - 615319 - 10/09/2024
The U.S. Food and Drug Administration issued a closeout letter to Missouri Analytical Laboratories Inc., confirming that the company’s corrective actions have addressed the violations cited in a 2021 warning letter. The FDA noted that while the immediate issues appear...
Lilly to Buy Startup Ajax in Bid for a Better JAK Drug
Eli Lilly announced it will acquire New York‑based biotech Ajax Therapeutics for up to $2.3 billion. The deal centers on Ajax’s experimental JAK inhibitor AJ1‑11095, which binds an inactive JAK2 conformation to overcome resistance seen with existing therapies for myelofibrosis and...
FDA Grand Rounds – Anti-Biofilm Technologies for Enhancing the Safety of Medical Device Surfaces - 05/29/2025
On May 29, 2025, the FDA hosted a Grand Rounds webcast on anti‑biofilm technologies for medical device surfaces, presented by Dr. Jayaleka J. Amarasinghe, a microbiologist at the agency’s Winchester Engineering and Analytical Center. The session highlighted two emerging strategies...
Bacterial Defense System Builds DNA in Unexpected New Way to Stop Viruses
Scientists at Stanford have identified a bacterial antiphage system called DRT3 that synthesizes double‑stranded DNA with a precise GT/AC repeat pattern. The system relies on two reverse transcriptases: Drt3a copies an RNA template, while Drt3b builds its complementary strand using...
Score Single-Cell Pathways with ssGSEA, GSVA, AUCell, UCell
1/15 Want to decode pathway activity in single cells? Understand ssGSEA, GSVA, AUCell, and UCell—tools that score gene sets per cell. Here's how they work 🧵 https://t.co/FIOA8YHBcl
Fathom Therapeutics Scores $47 Million Series A
Fathom Therapeutics, previously known as Atommap Corp., announced an oversubscribed $47 million Series A round. The financing was led by Sutter Hill Ventures with participation from Chemistry, Alexandria Venture Investments, and NY Ventures. Fathom leverages quantum chemistry and artificial intelligence to design...